Gain Therapeutics, Inc. — fact timeline

Gain Therapeutics, Inc. reported first quarter ended March 31, 2026 results: EPS $0.13 per share, basic and diluted.

“Net loss for the three months ended March 31, 2026, was $0.13 per share, basic and diluted, compared to $0.16 per share, basic and diluted, for the three months ended March 31, 2025.”

Gain Therapeutics, Inc. reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $20.2 million, or $0.61 per share, basic and diluted, EPS $0.61 per share, basic and diluted.

“Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update BETHESDA, MD, March 26, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update.”

Gain Therapeutics, Inc.: Increased authorized shares of common stock from 50,000,000 to 100,000,000 (effective 2025-06-24).

“On June 24, 2025, Gain Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 50,000,000 shares to 100,000,000 shares.”

Gain Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“f The Nasdaq Stock Market (“Nasdaq”) notifying the Company that that from November 14, 2024 to December 27, 2024, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The MVLS Deficiency Notice had no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Global Market under the symbol “GANX.” As of January 14, 2025, the Company has regained compliance”

Gain Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“um of $50 million required for continued listing on The Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The MVLS Deficiency Notice had no immediate effect on the listing of t”

Gene Mack was appointed as President and Chief Executive Officer at Gain Therapeutics, Inc..

“announced that Gene Mack has been appointed the Company’s President and Chief Executive Officer and a member of the Company’s board of directors (the “Board of Directors”), effective January 6, 2025.”

Khalid Islam was appointed as Executive Chairman of the Board at Gain Therapeutics, Inc..

“On June 27, 2024, Dr. Khalid Islam (“Dr. Islam”), the current Chairman of the Board, was appointed to serve as Executive Chairman of the Board, effective June 25, 2024.”

Gene Mack was appointed as Interim Chief Executive Officer at Gain Therapeutics, Inc..

“On June 27, 2024, Mr. Gene Mack (“Mr. Mack”), the Company’s current Chief Financial Officer, was appointed to serve as Interim Chief Executive Officer (“Interim CEO”), effective as June 25, 2024, to fill the vacancy created by Mr. Alder’s departure as Chief Executive Officer.”

Matthias Alder was terminated as Chief Executive Officer at Gain Therapeutics, Inc..

“On June 25, 2024, Matthias Alder (“Mr. Alder”), Chief Executive Officer of Gain Therapeutics, Inc. (the “Company”), and the Company mutually agreed that his service as Chief Executive Officer of the Company would terminate so that Mr. Alder can pursue other opportunities.”

Gianluca Fuggetta changed role as Principal Financial Officer at Gain Therapeutics, Inc..

“Upon Mr. Mack’s appointment, Gianluca Fuggetta, who had been serving as the Company’s Principal Financial Officer since March 1, 2024, will no longer serve in that capacity and will continue in his role as the Company’s Vice President of Finance and Principal Accounting Officer.”

Gene Mack was appointed as Chief Financial Officer at Gain Therapeutics, Inc..

“On April 5, 2024, Gain Therapeutics, Inc. (the “Company”) appointed Gene Mack as its Chief Financial Officer, to be effective as of April 8, 2024”

Gain Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $22.3 million, EPS $1.71.

“Net loss for the year ended December 31, 2023 was $22.3 million, compared to a net loss of $17.6 million for the year ended December 31, 2022.”

Gianluca Fuggetta was appointed as Vice President of Finance, Principal Financial Officer at Gain Therapeutics, Inc..

“On February 21, 2024, the Board of Directors of the Company appointed Gianluca Fuggetta, the Company’s current Senior Director, Finance & Corporate Reporting and Principal Accounting Officer, as the Company’s Vice President of Finance and to also serve as the Company’s Principal Financial Officer, to be effective March 1, 2024.”

C. Evan Ballantyne resigned as Chief Financial Officer at Gain Therapeutics, Inc..

“On February 19, 2024, Gain Therapeutics, Inc. (the “Company”) received notice of the resignation of C. Evan Ballantyne as the Company’s Chief Financial Officer, and all other positions held at the Company, to be effective March 1, 2024.”

Gain Therapeutics, Inc. entered into Securities Purchase Agreement with an accredited investor valued at aggregate gross proceeds of $5.0 million (effective 2023-11-21).

“On November 21, 2023, in a private placement (the “ Concurrent Private Offering ”) to be completed concurrently with the completion of the Offering, the Company entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor (“ Private Purchaser ”) whereby the Company will issue an aggregate of (i) 744,026 shares of Common Stock (the “ Private Shares ”), (ii) pre-funded warrants (the “ Pre-Funded Warrants ”) exercisable for an aggregate of up to 1,756,062 shares of Common Stock and (iii) warrants (the “ Private Warrants ”) to purchase up to an aggregate of 2,500,088 shares of the Company’s common stock (“ Private Warrant Shares ”) for aggregate gross proceeds of $5.0 million.”

Gain Therapeutics, Inc. entered into Underwriting Agreement with Newbridge Securities Corporation valued at aggregate gross proceeds of $4.4 million (effective 2023-11-21).

“On November 21, 2023, Gain Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Newbridge Securities Corporation, as the underwriter named therein (the “ Underwriter ”), relating to the offering, issuance and sale of an aggregate of (i) 2,213,044 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”) and (ii) warrants to purchase 1,106,522 shares of Common Stock (the “ Warrants ” and the shares of Common Stock underlying the Warrants, the “ Warrant Shares ”) for aggregate gross proceeds of $4.4 million (the “ Offering ”).”

Gain Therapeutics, Inc. terminated Sales Agreement with Cantor Fitzgerald & Co. (effective 2023-11-13).

“On November 13, 2023, Gain Therapeutics, Inc. (the “ Company ”) notified Cantor Fitzgerald & Co. (“ Cantor ”) of its decision to terminate the Controlled Equity Offering SM Sales Agreement, dated as of May 18, 2022, (the “ Sales Agreement ”) between the Company and Cantor, effective immediately (the “ Termination Date ”).”

Gain Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income $4.7 million, or $0.37 per share basic and diluted, EPS $0.37 per share basic and diluted.

“On November 14, 2023, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023, and business update.”

Gain Therapeutics, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023, was $7.7 million, or $0.62 per share basic and diluted, EPS $0.62 per share basic and diluted.

“Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate progress.”

Gain Therapeutics, Inc. shareholders approved Ratification of selection of Ernst & Young AG as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-23 meeting.

“Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Ernst & Young AG as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2023 The Company’s stockholders approved Proposal 2. The votes cast were as follows: For Against Abstain 7,927,104 4,642 11,513”

Gain Therapeutics, Inc. shareholders approved Election of eight nominees for director to serve until 2024 Annual Meeting at the 2023-06-23 meeting.

“Proposal 1 - Election of Directors The Company’s stockholders elected the eight persons listed below as directors, each to serve until the Company’s 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows: Nominees For Withheld Broker Non-Votes Matthias Alder 3,718,412 19,996 4,204,851 Dov Goldstein, M.D. 3,659,322 79,086 4,204,851 Hans Peter Hasler 3,491,745 246,663 4,204,851 Khalid Islam, Ph.D. 3,684,791 53,617 4,204,851 Gwen Melincoff 3,719,922 18,486 4,204,851 Claude Nicaise, M.D. 3,648,185 90,223 4,204,851 Eric I. Richman 3,711,215 27,193 4,204,851 Jeffrey Riley 3,716,202 22,206 4,204,851”

Gain Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $55,180, net income $5.1 million, EPS $0.43 per share basic and diluted.

“CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2023 2022 Revenues: ​ ​ ​ Collaboration revenues ​ $ 55,180 ​ $ 37,538 ​ Other income ​ - ​ 7,468 ​ Total revenues ​ ​ 55,180 ​ ​ 45,006 ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ Research and development ​ ​ (2,791,205”

Salvatore Calabrese was terminated as Chief Financial Officer at Gain Therapeutics, Inc..

“Mr. Calabrese’s employment terminates effective April 30, 2023”

Salvatore Calabrese was terminated as Chief Financial Officer at Gain Therapeutics, Inc..

“the Company informed Salvatore Calabrese, the Company’s former Chief Financial Officer, that his service as Chief Financial Officer of the Company would terminate effective as of the Transition Date.”

C. Evan Ballantyne was appointed as Chief Financial Officer at Gain Therapeutics, Inc..

“announced the appointment of C. Evan Ballantyne as its Chief Financial Officer, effective as of April 10, 2023”

Gain Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $140,108, net income $17.59 million, EPS $1.48.

“(audited) ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Revenues: ​ ​ ​ Collaboration revenues ​ $ 132,640 ​ $ 133,928 Other income ​ ​ 7,468 ​ 31,066 Total revenues ​ ​ 140,108 ​ ​ 164,994 ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ Research and development ​ (8,377,290) ​ (7,164,229) General and administrative ​ (9,539,863) ​ (6,826,938) Total operating”

Salvatore Calabrese changed role as Principal Accounting Officer at Gain Therapeutics, Inc..

“The Company’s Chief Financial Officer, Salvatore Calabrese, who was previously serving as both Principal Financial Officer and Principal Accounting Officer, will continue serving as the Company's Principal Financial Officer.”

Gianluca Fuggetta was appointed as Principal Accounting Officer at Gain Therapeutics, Inc..

“On December 12, 2022, Gain Therapeutics, Inc. (the " Company ") appointed Gianluca Fuggetta, its Finance Director, Corporate Reporting, as the Company's Principal Accounting Officer.”

Gain Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.

“On November 10, 2022, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022, and business update.”

Matthias Alder was appointed as Director at Gain Therapeutics, Inc..

“Matthias Alder, the Company’s former Chief Operating Officer, has been appointed by the Board to serve as the Company’s President and Chief Executive Officer and as a member of the Board, in each case effective September 20, 2022”

Matthias Alder was appointed as President and Chief Executive Officer at Gain Therapeutics, Inc..

“Matthias Alder, the Company’s former Chief Operating Officer, has been appointed by the Board to serve as the Company’s President and Chief Executive Officer and as a member of the Board, in each case effective September 20, 2022”

Eric Richman resigned as Chief Executive Officer at Gain Therapeutics, Inc..

“Eric Richman informed the Board of Directors (the “Board”) of his intent to resign as Chief Executive Officer, effective immediately.”